Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Palau , American , Garcia Soria , Nevarez Ruiz , J Clin Endocrinol , Acta Physiol , European Association For The Study Of Diabetes , American Diabetes Association , European Association , Englj Med , Diabetes Endocrinol , Obes Metab , Endocrinol Metab , Clin Endocrinol Metab ,